Ending the Affordable Care Act’s cost-sharing subsidies would harm patients’ finances and health, trigger a “death spiral” in the health insurance exchanges, and force hospitals to shoulder an even greater financial burden, making it harder for them to serve their communities, the AHA, Federation of American Hospitals, The Catholic Health Association of the United States, and Association of American Medical Colleges said in a friend-of-the-court brief filed Saturday in State of California, et al., v. Donald J. Trump, et al. “All of this suggests that the cost-sharing subsidies provided for under the Act should continue to be made,” the brief states. “Congress meant for the Act to create exchanges where lower-income patients could purchase affordable insurance that they could actually use. Without the subsidy payments, government expenditures under the Act will increase, which would be in tension with the Act’s goals.” Filed by attorneys general in California and 18 other states, the lawsuit seeks to prevent the administration from ending the cost-sharing subsidy payments.

Related News Articles

Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The American Medical Association Dec. 16 released its latest annual report on health insurance competition, finding that 97% of commercial markets were highly…
Headline
Approximately 950,000 consumers who currently do not have health insurance coverage through the federally facilitated Health Insurance Marketplace have signed…
Headline
The Senate today failed to pass legislation to address health care affordability. The chamber first voted on a Republican-backed bill that failed by a 51-…
Headline
The AHA Dec. 9 expressed support for the Critical Access for Veterans Care Act (S. 1868), legislation that would expand veteran access to critical access…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…